Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

PRESS: What to Consider with Confidentiality Agreements <i>(Upstart Business Journal)</i>

PRESS: What to Consider with Confidentiality Agreements (Upstart Business Journal)

Related Content

Genentech/Hoffmann La-Roche and Shanghai Henlius Biotech/Organon Settle Pertuzumab BPCIA Case

European Biologic and Biosimilar Updates

Antitrust and Competition Life Sciences Year in Review 2025

FDA Issues Guidance on Modernizing Statistical Methods for Clinical Trials

AbbVie and Novartis Announce Billion Dollar Licensing Deals for Oncology and Alzheimer’s Treatments

Top 10 Issues in Cross-Border Life Sciences Transactions

Enforcement Intensifies as Medicaid Cuts Take Hold

CMS Finalizes Changes to Bona Fide Service Fee Requirements, Alongside Other Adjustments to Medicare Part B Drug Reimbursement Methodology (Employee Benefit Plan Review)

The Future of Life Sciences Antitrust

Goodwin Advises Orna Therapeutics in Acquisition by Eli Lilly for Up to $2.4 Billion

Goodwin Advises Agomab on Pricing of $200 Million Initial Public Offering

Goodwin Continues to Lead 2025 League Tables

Chambers France 2026 Recognizes Goodwin Paris

Goodwin Advises Moderna on Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927) for $50 Million Upfront and Up to $110 Million in Milestones in Addition to Tiered Royalties on Net Sales

Goodwin Guides Repertoire Immune Medicines on a Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases for $85 Million Upfront, Up to $1.84 Billion in Milestones, and Potential Tiered Royalties

Goodwin Advises Tenpoint Therapeutics on Securing $235 Million Through Series B Stock Financing and Credit Facility

Life Sciences

Technology